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ABSTRACT
This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, pro-
phylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to the risk of 
hepatitis B reactivation emergency. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, 
academicians from several university health research and training centers across Turkey came together and discussed the importance 
of the subject, current status, and issues in accordance with the current literature data and presented solutions. 
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INTRODUCTION
The subject was addressed and interpreted under the fol-
lowing main titles:
1. The prevalence of hepatitis B in Turkey
2. How to interpret hepatitis B serology
3. The definition and the outcomes of hepatitis B reac-
tivation
4. The reactivation risk rate by serological status
5. The reactivation risk rate by immunosuppressive dis-
eases
6. The reactivation risk rate by immunosuppressive 
agents
7. How to screen for the risk of hepatitis B reactivation
8. How to administer prophylaxis for hepatitis B reacti-
vation and which agents should be used
9. How to treat a reactivated patient
At the end of the consensus report, an algorithm summa-
rizing the approach for treating patients with the risk of 
hepatitis B reactivation due to immunosuppressive ther-
apy is included (Figure 1).
1. The prevalence of Hepatitis B in Turkey
In Turkey, one of the most important studies on Hepatitis 
B virus (HBV) epidemiology was conducted by the Turk-
ish Association for the Study of the Liver in 23 provinces 
that screened a total of 5460 individuals between 2009 
and 2010. In the adult (≥18 years) age group, 4% hep-
atitis B surface antigen (HBsAg) positivity, 30.6% total 
hepatitis B core antigen-antibody (anti-HBc) positivity, 
and 31.9% antibodies against HBsAg (anti-HBs) positivi-
ty was detected (1). According to these rates, there were 
2,060,000 HBsAg-positive adults in Turkey in 2010 (2). 
These results indicate that HBV is moderately frequent 
in Turkey. HBV accounts for approximately 40%-45% of 
chronic hepatitis and liver cirrhosis cases; and together 
with hepatitis D virus, the ratio reaches up to half of the 
patients. A total of 15,760,000 individuals correspond-
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ing to approximately one third of the adult population 
showed an encounter with HBV, indicating that these in-
dividuals carry covalently closed circular DNA (cccDNA) 
of the virus in their liver. Furthermore, according to the 
results of this epidemiological study, only 26% of individ-
uals are aware that they are HBV carriers (1). To solve this 
issue of low awareness, the individuals in the risk groups 
should be efficiently and accurately screened.
In conclusion, HBV is moderately frequent in our coun-
try. The rate of individuals who are aware that they are 
HBV carriers is relatively low. To solve this issue of low 
awareness, the individuals in the risk groups should be ef-
ficiently screened. 
2. How to interpret Hepatitis B serology
HBV is associated with several antigens and antibodies. 
The different stages of the infection can be diagnosed 
by exploiting the combinations of these antigens and 
antibodies. HBV has three major antigens:
• HBsAg: Hepatitis B surface antigen
• HBeAg: Hepatitis B e antigen
• HBcAg: Hepatitis B core antigen. This antigen is ab-
sent in the blood and is found in hepatocytes.
There are three major antibodies formed against HBV:
• Anti-HBs: Antibody against HBsAg
• Anti-HBe: Antibody against HBeAg
• Anti-HBc: Antibody against HBcAg. It is called 
anti-HBc IgM if it is formed in the acute phase and 
anti-HBc IgG if it emerges after the acute phase of 
the disease.
HBsAg: It is the first antigen that appears in the blood 
during the acute phase of infection. It is the only indicator 
that can be detected in the blood within approximately 
3-5 weeks after the virus exposure and may be detected 
in the blood for 4-14 weeks. (3). A positive result in the 
workup is suggestive of two conditions:
(1) It reflects the acute phase of infection in patients 
whose clinical presentation and laboratory findings are 
consistent with B-type acute viral hepatitis (AVH). The 
diagnosis of B-type AVH cannot be made only on the ba-
sis of the positivity of this test.
(2) If immunity does not develop after the disease and 
HBsAg positivity lasts for more than 6 months, it is called 
chronic HBV infection. These patients may present with the 
following conditions: HBeAg-positive chronic infection or 
chronic hepatitis B (CHB), HBeAg-negative chronic infec-
tion or CHB, occult hepatitis, liver cirrhosis, and liver cancer.
HBeAg: It emerges in the acute phase after HBsAg and 
is cleared from the bloodstream before the clearance of 
HBsAg. Its presence in the blood indicates actively rep-
licating virus and a high level of infectivity. In the acute 
phase it remains in the blood for 10 weeks and its per-
sistence suggests chronicity. When HBeAg becomes 
negative, anti-HBe usually becomes positive. HBeAg 
negativity occurs in HBeAg-negative chronic HBV infec-
tion and HBeAg-negative chronic hepatitis B phases of 
chronic HBV infection. In HBeAg-negative chronic HBV 
infection, HBV DNA titer is <2000 IU/mL and alanine ami-
notransferase (ALT) is normal, indicating the absence of 
liver disease. Conversely, in HBeAg-negative chronic hep-
atitis B, HBeAg is lost due to precore and/or basal core 
promoter mutations. This phase is characterized by the 
continuous or intermittent HBV DNA of >2000 IU/mL 
and ALT elevation, indicating that liver disease has already 
developed (4). CHB cases can be divided into two groups: 
HBeAg-positive and HBeAg-negative. Approximately 
75% of CHB cases in our country are HBeAg-negative.
Anti-HBc: It is the first antibody formed during the course 
of the disease. It may be present in all cases: acute, chronic, 
and immunized. Anti-HBc IgM positivity is the most reliable 
indicator of the acute phase. In some cases, when HBsAg 
rapidly becomes undetectable, anti-HBs becomes detect-
able. In an acute phase, these two tests may be negative. 
This period is called the “window period” and, anti-HBc IgM 
test is positive. A positive anti-HBc IgG test indicates that 
the individual has encountered HBV. As anti-HBc IgG is the 
most reliable indicator of the infection, it is an excellent 
screening test to reveal whether an individual has encoun-
tered HBV or not. Even if the patient has been immunized 
after the virus is cleared from the blood, it remains positive 
throughout life, although in a low titer. If anti-HBc IgG is 
found to be negative after the tests, it suggests that the 
individual has never encountered the virus; if HBsAg is neg-
ative and anti-HBs is positive, it suggests that the individual 
has been vaccinated.
Anti-HBe: It emerges after the development of antibod-
ies against HBcAg. It may be positive in immunized indi-
viduals, inactive carriers, and the majority of patients with 
chronic hepatitis.
Anti-HBs: It emerges in the convalescent period. It may not 
get positive in 5%-10% of the cases after acute hepati-
tis. It reflects immunization and remains positive for life. If 
HBsAg does not become undetectable in six months in the 
blood after acute infection and anti-HBs does not emerge, 
chronicity must be suspected. Anti-HBs positivity may de-
velop by a natural encounter with the virus or vaccination.
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HBV DNA: It is the most reliable indicator of viral replica-
tion. It can be detected quantitatively (IU/mL) using poly-
merase chain reaction. In acute infection, it can be de-
tected in the blood 10-20 days before HBsAg detection 
(5). It usually becomes undetectable in acute phase upon 
symptom onset. In inactive carriers, it is usually <2000 IU/
mL.
The European Association for the Study of Liver (EASL) 
guideline divides chronic HBV infection into five phases 
(4):
Phase 1: HBeAg-positive chronic HBV infection
Phase 2: HBeAg-positive chronic hepatitis B
Phase 3: HBeAg-negative chronic HBV infection
Phase 4: HBeAg-negative chronic hepatitis B
Phase 5: HBsAg-negative phase
Phase 1: HBeAg-positive chronic HBV infection. Previ-
ously, it was called as the “immune tolerant” phase. It is 
characterized by the presence of HBeAg in serum, very 
high level of HBV DNA, and chronic normal ALT level (≤40 
IU/mL).
Phase 2: HBeAg-positive chronic hepatitis B. It is char-
acterized by the presence of HBeAg in serum, high level 
of HBV DNA, and elevated ALT.
Phase 3: HBeAg-negative chronic HBV infection. Pre-
viously, it was called as the “inactive carrier” phase. It 
is characterized by the presence of antibodies against 
HBeAg (anti-HBe) in serum, undetectable or low (<2.000 
IU/mL) levels of HBV DNA, and normal ALT level (≤40 IU/
mL).
Phase 4: HBeAg-negative chronic hepatitis B. It is char-
acterized by usually detectable anti-HBe together with 
the absence of HBeAg in serum, persistent or fluctuating 
moderate-to-high serum HBV DNA levels (mostly lower 
than HBeAg-positive patients), and fluctuating or per-
sistent high ALT levels.
Phase 5: HBsAg-negative phase. It is characterized by 
HBsAg negativity in serum with the presence of antibody 
against HBcAg (anti-HBc) positivity with or without de-
tectable antibody against HBsAg (anti-HBs). If low levels 
of HBV DNA positivity is present, it is called an “occult 
HBV infection.”
Serological and virological results at various phases of 
HBV infection are given in Table 1.
In conclusion, by interpreting different combinations of 
HBV antigens and antibodies, the different stages of the 
infection can be diagnosed and risks can be identified.
3. The definition and the outcomes of Hepatitis B reactivation
HBV reactivation is the emergence of a necroinflam-
matory liver disease along with increased viral replica-
tion in patients with inactive or resolved HBV infection or 
HBeAg-negative CHB. HBV reactivations may occur under 
immunosuppression (immunosuppressive therapy, cancer 
chemotherapy, transplantation, after pregnancy, and HIV 
infection) due to medication-induced reasons (under in-
terferon therapy, with resistance to or discontinuation of 
oral antiviral agents) and in the natural course of the dis-
ease (during the conversion from HBeAg-positive chronic 
HBV infection to HBeAg-positive CHB, during HBeAg and 
HBsAg seroconversions, and with basal core promoter and 
precore mutations). The increased viral replication during 
immunosuppressive therapy or cancer chemotherapy re-
sults in liver damage during immune reconstitution (6,7). 
HBV reactivation has three phases:
Phase 1- increased viral replication: It is the phase right af-
ter immunosuppression. Increase in HBV DNA (>log10 IU/
ml), HBeAg positivity in patients who were previously HBeAg 
negative and HBsAg positivity accompanying reverse sero-
conversion is observed. This phase can be summarized as 
follows (8):
• In HBsAg-positive and HBV DNA-positive patient  
HBV DNA increases
• In HBsAg-positive and HBV DNA-negative patient 
 HBV DNA becomes positive
• In HBsAg-negative and anti-HBc-positive patient 
 HBsAg becomes positive (reverse seroconver-
sion) or HBV DNA becomes positive with HBsAg re-
maining negative
Phase 2- hepatic injury period: Liver damage usually oc-
curs upon the discontinuation, interruption, or dose re-
duction phases of immunosuppression. ALT level increas-
es (3-fold or more of the upper limit of normal) and HBV 
DNA starts to decrease; in severe cases, other symptoms 
showing jaundice and hepatic damage emerge. Some-
times, liver damage may also develop during the course 
of immunosuppression.
Phase 3- recovery period: Liver damage regresses, HBV 
DNA and ALT return to the baseline levels, and HBsAg may 
become negative in the late phase (6). Sometimes, hepa-
titis phase may persist, and chronic hepatitis may develop.
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HBV reactivation may result in the discontinuation of im-
munosuppressive agent or therapy. This discontinuation 
rate was found to be 71% in patients with reactivation 
due to chemotherapy and 33% in patients without reac-
tivation (8). Early discontinuation of the therapy results in 
increased morbidity and mortality caused by the primary 
disease. Furthermore, hepatitis at various grades may de-
velop in patients due to the immune activation triggered 
by the discontinuation of medications (8):
1. ALT levels may not change (silent type)
2. ALT levels may increase without the development of 
jaundice (mild type)
3. Jaundice may accompany the ALT increase (moder-
ate type)
4. Liver failure may accompany jaundice (severe type)
5. Fatal type
In conclusion, HBV reactivation may present with different 
manifestations ranging from asymptomatic to a severe and 
fatal clinical presentation and may result in the discontin-
uation of immunosuppression or chemotherapy. Early dis-
continuation of the therapy results in increased morbidity 
and mortality caused by the primary disease.
4. The reactivation risk rate by serological status
The risk of hepatitis B reactivation due to immunosup-
pressive therapy is closely associated with the presence 
of serological and virological hepatitis B markers in a pa-
tient. Among the risk factors, the strongest one is high HBV 
DNA (>2.000 IU/mL) level (9,10). Among the HBsAg and/or 
anti-HBc IgG-positive patients, the risk of reactivation is 
more in patients with a detectable or high level of HBV DNA 
than in those with a negative or low level of HBV DNA. The 
reactivation risk in HBsAg-positive patients is 8-fold more 
than in patients with isolated anti-HBc IgG positivity (11). 
The reactivation risk is more in HBeAg-positive patients 
than in negative patients (12). The rate of reactivation of 
genotype B and genotype C is more than that of genotype 
A (8,13). Although there are studies showing that high ti-
ters of anti-HBs antibody positivity is protective for Anti 
HBc IgG patients, current information states that neither 
anti HBs positivity nor titer is decisive while planning the 
antiviral treatment (14,15). Furthermore, the risk of HBV 
infection is more in individuals with HBsAg mutation than 
in those without it (16). Risk of reactivation by serological 
status is given in Table 2 (17).
In conclusion, the hepatitis B reactivation risk due to the 
immunosuppressive therapy is closely associated with 
the hepatitis B serology in patients.
5. The reactivation risk rate by immunosuppressive 
diseases
Malignant, inflammatory, and autoimmune diseases play 
a determinative role in the incidence of HBV reactivation 
(18). HBV reactivation rates in immunosuppressive dis-
eases and serological markers of HBV infection are sum-
marized in Table 3 (18).
In conclusion, malignant, inflammatory, and autoimmune 
diseases play a determinative role in the incidence of HBV 
reactivation.
6. The reactivation risk rate by immunosuppressive agents
The risk of HBV reactivation varies with the class of im-
munosuppressive medications. When medications sup-
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 HBsAg HBeAg Anti-HBc IgM Anti-HBc IgG Anti-HBe Anti-HBs HBV DNA (IU/mL)
Acute viral hepatitis Positive Positive Positive Negative Negative Negative Negative/Positive
Acute viral hepatitis-window period Negative Positive Positive Negative Negative Negative Negative/Positive
Immune to HBV (past infection) Negative Negative Negative Positive Positive Positive Negative
HBeAg-negative chronic HBV infection  Positive Negative Negative Positive Positive Negative <2000
HBeAg-positive chronic hepatitis B Positive Positive Negative Positive Negative Negative >2000
HBeAg-negative chronic hepatitis B Positive Negative Negative Positive Negative/Positive Negative >2000
Isolated anti-HBc positivity Negative Negative Negative Positive Negative Negative Negative
       Positive  
       (occult hepatitis)
Immune to HBV (vaccinated) Negative Negative Negative Negative Negative Positive Negative
Table 1. Serological and virological results at various phases of HBV infection
pressing B cells, anthracycline derivatives, and high-dose 
corticosteroid are used, the risk of reactivation is >10%. 
With the use of tumor necrosis factor-α (TNF-α), cyto-
kine, integrin, and tyrosine kinase inhibitors, and a modest 
dose of corticosteroid, the risk of reactivation varies be-
tween 1% and 10% depending on hepatitis B serology. In 
case of using a low-dose or intra-articular corticosteroid 
or conventional immunosuppressive medications (aza-
thioprine, 6-mercaptopurine, methotrexate), the risk of 
reactivation is <1% (18,19).
Antimetabolites
The number of reported antimetabolite-induced HBV 
reactivations is very low (20). Reactivation during azathi-
oprine or methotrexate use is rare. Antimetabolites are 
low-risk medications (21). The data regarding subjects 
using high-dose methotrexate is very limited (22).
TNF-α inhibitors
TNF-α inhibition may lead to increase of HBV replication 
(20). Anti-TNF-α medications include infliximab, adali-
mumab, certolizumab, golimumab, and etanercept. In a 
study investigating the incidence of HBV reactivation in 
468 patients with isolated anti-HBc positivity and ma-
jority of them using infliximab, the reactivation rate was 
1.7% (23). The incidence in HBsAg-positive patients was 
12.3%. Among TNF-α inhibitors, reactivation is reported 
more with infliximab and adalimumab than with etaner-
cept. When anti-TNF-α medications are used alone, the 
risk of reactivation varies between 1% and 10% depend-
ing on the hepatitis B serology of the patient (24).
Transarterial chemoembolization applications
Reactivation may also occur after transarterial chemo-
embolization procedure in patients with a mass in the 
liver. Although a chemotherapeutic agent is directly ad-
ministered into the mass in such cases, the reactivation 
with systemic involvement has been rarely reported (25). 
Anthracyclines (e.g., doxorubicin) are also given to the 
individuals receiving transarterial chemoembolization 
applications as a part of the treatment. Anthracycline de-
rivatives have been demonstrated to increase HBV DNA 
secretion in experimental studies (24).
Steroids
Steroid use is considered to be an independent risk factor 
for reactivation (26). Prednisolone is frequently used for 
the treatment of many inflammatory diseases. However, 
the use of these medications both as monotherapy and 
in a combination is accompanied by an increased HBV 
reactivation risk (26). Steroids decrease specific T-cell 
responses and increase the virus replication. The risk of 
infection is directly proportional to the duration and dose 
of the steroid (27). The levels of risk due to steroid use are 
listed in Table 4 (24).
Systemic chemotherapy
HBV reactivation is frequent during systemic chemother-
apy treatments. This is associated with the administered 
chemotherapeutic agent as well as the origin of cancer 
(hematological/non-hematological) (28). Individuals with 
hematological cancer are more prone to acquire HBV re-
activation, and these patients are considered to be at a 
high risk. For example, the reactivation incidence in lym-
phoma patients is up to 50% (28). During the treatment 
of hematological malignancy in HBsAg-positive patients, 
the risk of HBV reactivation has been reported to be 
40%-50% (29). The mortality rate in these patients after 
reactivation has been reported to be 4%-41% (26). This 
probability further increases, especially in regimens con-
taining high-dose steroids or rituximab (immunotherapy) 
(30). HBV reactivation has also been reported in patients 
with a solid tumor (e.g., breast, colon, lung cancer) (30). 
The reactivation risk in HBsAg positive patients who are 
receiving chemotherapy for a solid tumor is moderate. 
The risk of HBV reactivation in solid tumor varies by the 
administered therapy (31).
Biological antibodies
Patients using rituximab and ofatumumab, both of which 
are anti-CD 20 antibodies, have been found to be at 
high-risk for HBV reactivation (32). With the standard 
non-Hodgkin lymphoma treatment, the risk of reactiva-
tion is 25% even 12 months after the end of treatment 
(26). According to FDA data, many cases of HBV reac-
tivation have been reported due to the use of rituximab 
and ofatumumab; thus, these medications belong to the 
high-risk group. Therefore, in 2013, a warning stating that 
these medications may cause fulminant hepatitis, he-
patic failure, and death had been published. This warn-
ing applies not only to HBsAg-positive cases but also to 
HBsAg-negative/total anti-HBc IgG-positive cases with a 
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Risk status Serology
High HBsAg-positive, HBeAg-positive/negative, HBV  
 DNA>2000 IU/mL
Medium HBsAg-negative, Anti-HBc IgG-positive,  
 Anti-HBs-negative
Low HBsAg-negative, Anti-HBc IgG-positive,  
 Anti-HBs-positive
Table 2. Risk of reactivation by serological status
previous history of hepatitis B infection (26,32). Biological 
agents including tyrosine kinase inhibitors (e.g., imatinib, 
nilotinib, and dasatinib), cytokine, and integrin inhibitors 
(ustekinumab, natalizumab, alemtuzumab, vedolizumab) 
are associated with a moderate risk of HBV reactivation 
(24). Therefore, all of these agents should be cautiously 
considered.
Hemopoietic stem cell and organ recipients
Hemopoietic stem cell and organ recipients have the 
highest risk of HBV reactivation. These patients under-
go an intense immunosuppression. Therefore, they lose 
their previously acquired HBV immunity and have an 
increased (almost half) risk of HBV reactivation (both 
in HBsAg-positive and anti-HBc positive patients). In 
this patient group, chronic infection risk is high if virus 
reactivation occurs (33). In a retrospective study, 137 
HBsAg-negative and anti-HBc-positive cases were ex-
amined, and HBV reactivation was observed in 10% of 
them within 77 months after transplantation (34). The 
risk in complete organ recipients is high (50%-90%). Af-
ter transplantation, these patients should be followed-up 
for hepatic failure, progression to cirrhosis, and hepa-
tocellular cancer. In transplantation patients, the serol-
ogy of the donor is also important. In case the donor is 
anti-HBc IgG-positive, the recipient should receive anti-
viral prophylaxis (35).
HBV reactivation risk rates due to immunosuppressive 
agents are shown in Table 4 (24).
In conclusion, the risk of HBV reactivation varies with the 
class of immunosuppressive medications. When med-
ications suppressing B cells, anthracycline derivatives, 
and high-dose corticosteroids are used, the risk of reac-
tivation is >10%. With the use of TNF-α, cytokine, inte-
grin, and tyrosine kinase inhibitors, and a modest dose 
of corticosteroid, the risk of reactivation varies between 
1% and 10%. With the use of low-dose or intra-articular 
corticosteroid or conventional immunosuppressive med-
ications (azathioprine, 6-mercaptopurine, methotrexate), 
the risk of reactivation is even <1%.
7. How to screen for the risk of Hepatitis B reactivation
EASL, APASL (The Asian Pacific Association for the
Study of the Liver), and The Centers for Disease Con-
trol and Prevention (CDC) report that in countries with 
HBsAg prevalence of >2%, HBsAg, anti-HBc IgG, and 
anti-HBs screening must definitely be performed before 
any immunosuppressive therapy (36-38). In patients 
who are going to receive immunosuppressive therapy or 
chemotherapy, screening before the treatment to avoid 
HBV reactivation is highly recommended (18). This strat-
egy provides following benefits:
• Antiviral prophylaxis
• HBV serology and HBV monitorization (without an-
tiviral therapy)
• Immunization against HBV
• Evaluation of HBV complications
• Contacting other family members for chronic HBV 
and planning their treatment as required
During the screening, HBsAg, anti-HBc, and anti-HBs 
tests must be performed. If HBsAg or anti-HBc is posi-
tive, HBV DNA must be studied.
In conclusion, in patients who are going to undergo im-
munosuppressive therapy, HBsAg, anti-HBc IgG, and 
anti-HBs screening must be performed before the treat-
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 Incidence of HBV reactivation  
 in individuals not receiving  
 prophylaxis
  HBsAg-negative/ 
 HBsAg anti-HBc- 
Disease positive positive (%)
Lymphoma 18-73 34-68
Acute leukemias 61 2.8-12.5
Chronic leukemias ND* ND*
Multiple myeloma ND* 6.8-8
Bone marrow/hematopoietic  66-81 6-10 
stem cell transplantation 
Breast cancer 21-41 ND*
Nasopharyngeal cancer 33 ND*
Hepatocellular cancer  
(systemic chemotherapy) 36 11
Hepatocellular cancer (transarterial  21-30 9.3 
chemoembolization) 
Rheumatoid arthritis 12.3 3-5
Psoriasis/psoriatic arthritis ND* ND*
Inflammatory bowel diseases 36 0-7**
Autoimmune diseases ND* 17**
Renal transplantation 45-70 0.9
*No data; **Case reports or small case series
Table 3. The incidence of HBV reactivation by immunosup-
pressive disease
ment to avoid HBV reactivation. If HBsAg or anti-HBc is 
positive, HBV DNA must be studied.
8. How to administer prophylaxis for Hepatitis B reacti-
vation and which agents should be used
Randomized trials have shown that prophylactic antivi-
ral therapy is more effective than pre-emptive strategies 
(39). The timing of prophylaxis and choice of antiviral 
agent depends on the risk of reactivation, planned dura-
tion of chemotherapy, level of HBV DNA, and previous an-
tiviral therapy (if available) (40). HBV prophylaxis should 
be initiated 1-3 weeks before the immunosuppressive 
therapy, if possible, or at least concomitantly with the im-
munosuppressive therapy (7,36,37,40).
Two weeks after the initiation of antiviral therapy, the sup-
pression of HBV DNA by more than 2 log increases the 
possibility of survival in the patients. In case of active hep-
atitis, chemotherapy can be delayed until transaminase 
level becomes less than 3 fold of normal level (40,41).
Prophylactic therapy should be continued for addition-
al 12 months after the discontinuation of immunosup-
pressive therapies (7,19,36,37,42). If immunosuppres-
265
Turk J Gastroenterol 2018; 29: 259-69 Aygen et al. Immunosuppressive therapy & HBV reactivation risk
HBV reactivation risk rate Medication group Medication
High (>10%) Medications causing B-cell suppression Rituximab 
  Ofatumumab 
 Anthracycline derivatives  Doxorubicin 
  Epirubicin (HBsAg-positive/anti-HBc-positive)
 Corticosteroids ≥4 weeks, HBsAg-positive/anti-HBc-positive,  
  moderate/high dose (10-20 mg/>20 mg)




 Other cytokine inhibitors and  Abatacept 
 integrin inhibitors Ustekinumab
  Natalizumab
  Vedolizumab 
 Tyrosine kinase inhibitors Imatinib
  Nilotinib
 Anthracycline derivatives Doxorubicin
  Epirubicin (HBsAg-negative/anti-HBc-positive)
 Corticosteroids ≥4 weeks, HBsAg-positive/anti-HBc-positive, low  
  dose (<10 mg)
 Corticosteroids ≥4 weeks, HBsAg-negative/anti-HBc-positive,  
  moderate/high dose (10-20 mg/>20 mg)
Low (<1%) Conventional immunosuppression Azathioprine
  6-mercaptopurine
  Methotrexate 
 Intra-articular corticosteroids 
 Corticosteroids ≤1 week
 Corticosteroids ≥4 weeks, HBsAg-negative/anti-HBc-positive, low  
  dose (<10 mg)
Table 4. HBV reactivation risk rates by medication groups
sion is going to last for a long period, prophylaxis should 
not be discontinued (6). Administering lifelong prophy-
laxis after liver transplantation is the standard approach 
(7,36).
The ideal oral antiviral agents that can be used for pro-
phylaxis are entecavir and tenofovir. Compared with the 
other nucleos(t)ide analogs, such as lamivudine, adefo-
vir, and telbivudine, these two agents are more potent 
in terms of HBV DNA suppression and also have a high 
genetic barrier against the development of medication 
resistance and exert rapid action. Therefore, these agents 
should be preferred in all patients for prophylaxis against 
HBV reactivation (36,43,44).
Patients should be monitored by liver tests, and HBV 
DNA analysis should be performed every 3 months 
during the prophylaxis and for at least 12 months after 
the discontinuation (4,8). HBsAg-negative and anti-HBc 
IgG-positive (anti-HBs-positive or -negative) patients 
with negative HBV DNA who do not receive prophylax-
is are recommended to be monitored by liver tests every 
1-3 months and by HBV DNA every 3 months until 6-12 
months after the end of immunosuppressive therapy 
(36). Patients who are not receiving prophylaxis should 
also be monitored in a similar manner.
In conclusion, prophylactic antiviral therapy is more effective 
than pre-emptive strategies. The ideal approach is to start 
HBV prophylaxis before immunosuppressive therapy. Ente-
cavir and tenofovir, which potently suppress HBV DNA and 
have a strong genetic barrier against resistance development 
and exert rapid actions, should be preferred for prophylaxis.
9. How to treat a reactivation patient
If HBV reactivation is detected during chemotherapy or 
immunosuppressive therapy, the treatment is delayed or 
may be discontinued. The decision of treatment interrup-
tion depends on the severity of the clinical presentation. 
Except for the silent type and mild type, when the patients 
show transaminase levels below 5-fold, the treatment is in-
terrupted. The treatment should also be interrupted in pa-
tients showing serum ALT/AST levels above 3-fold in pres-
ence of symptoms or jaundice (8,24,41,45). Chemotherapy 
discontinuation may decrease or stop the rate of HBV rep-
lication. In the absence of antiviral prophylaxis, HBV reac-
tivation may occur in immune reconstitution phase after 
chemotherapy. The interruption of chemotherapy or im-
munosuppressive therapy due to reactivation may pose a 
great risk for the primary disease (46). Therefore, a proper 
evaluation of prophylaxis requirements for patients before 
chemotherapy is important.
If HBV reactivation occurs, antiviral therapy should be ini-
tiated as soon as possible. In some cases, patients may 
be asymptomatic, whereas 25%-50% of them may de-
velop severe hepatitis and hepatic failure. Tenofovir or 
entecavir are the recommended agents, and the decision 
for the treatment can be based on the patient’s condition 
and renal functions. In patients who have previously used 
lamivudine, tenofovir should be preferred (47).
In conclusion, reactivation is a serious and fatal condition, 
and the response to antiviral therapies administered after 
reactivation is not enough. Furthermore, the discontinua-
tion of immunosuppressive medication causing reactiva-
tion may result in the progression of the primary disease. 
Therefore, initiating antiviral prophylaxis before immuno-
suppressive therapy or chemotherapy can be lifesaving.
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RECOMMENDATION
In patients who are going to undergo immunosup-
pressive therapy, HBsAg, anti-HBc IgG, and anti-HBs 
screening must be performed before treatment. 
However, this screening is ignored most of the time, 
and patients face severe outcomes of reactivation. 
To avoid putting these patients at risk, establishing 
a central warning system in the hospital computer 
system and ensuring that the necessary screening 
is performed before the initiation of immunosup-
pressive therapy via a reminder showing up on the 
screens of the related branch specialists might be 
beneficial.
It should be remembered that prophylactic antivi-
ral therapy for a suitable patient may be lifesaving.
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